eXoZymes, Inc.EXOZ
▼ NegativeCapitalrelevance
Net loss widened and cash runway only through end of 2026.
Impact on stocks 1
Synthetic Biology (non-pharma)
eXoZymes, Inc.eXoZymes reported its second quarter 2026 results. Operating expenses for the second quarter of 2026 were $2.95 million, compared with $2.55 million for the same period in 2025. Net loss was $2.88 million for the quarter and $5.25 million for the six months ended June 30, 2026. The Company ended the quarter with $5.65 million in cash and cash equivalents, which the Company expects will support operations through the end of 2026.
eXoZymes, Inc.Net loss widened and cash runway only through end of 2026.